Cover Page
Cover Page | 9 Months Ended |
Sep. 30, 2021 | |
Cover [Abstract] | |
Document Type | 6-K |
Amendment Flag | false |
Document Period End Date | Sep. 30, 2021 |
Document Fiscal Year Focus | 2021 |
Document Fiscal Period Focus | Q3 |
Entity Registrant Name | NUCANA PLC |
Entity Central Index Key | 0001709626 |
Current Fiscal Year End Date | --12-31 |
Unaudited Condensed Consolidate
Unaudited Condensed Consolidated Statements of Operations - GBP (£) £ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Profit or loss [abstract] | ||||
Research and development expenses | £ (8,971) | £ (6,117) | £ (26,200) | £ (17,918) |
Administrative expenses | (2,277) | (1,906) | (6,456) | (5,144) |
Net foreign exchange gains (losses) | 1,274 | (1,601) | 488 | 610 |
Operating loss | (9,974) | (9,624) | (32,168) | (22,452) |
Finance income | 22 | 26 | 81 | 234 |
Loss before tax | (9,952) | (9,598) | (32,087) | (22,218) |
Income tax credit | 1,911 | 1,204 | 5,198 | 3,797 |
Loss for the period | £ (8,041) | £ (8,394) | £ (26,889) | £ (18,421) |
Basic and diluted loss per share | £ (0.15) | £ (0.24) | £ (0.52) | £ (0.55) |
Unaudited Condensed Consolida_2
Unaudited Condensed Consolidated Statements of Comprehensive Loss - GBP (£) £ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Statement of comprehensive income [abstract] | ||||
Loss for the period | £ (8,041) | £ (8,394) | £ (26,889) | £ (18,421) |
Items that may be reclassified subsequently to profit or loss: | ||||
Exchange differences on translation of foreign operations | 10 | (15) | 6 | 7 |
Other comprehensive income (expense) for the period | 10 | (15) | 6 | 7 |
Total comprehensive loss for the period | (8,031) | (8,409) | (26,883) | (18,414) |
Attributable to: | ||||
Equity holders of the Company | £ (8,031) | £ (8,409) | £ (26,883) | £ (18,414) |
Unaudited Condensed Consolida_3
Unaudited Condensed Consolidated Statements of Financial Position - GBP (£) £ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Non-current assets | ||
Intangible assets | £ 4,896 | £ 4,753 |
Property, plant and equipment | 952 | 1,189 |
Deferred tax asset | 34 | 44 |
Other non-current assets | 2,600 | 0 |
Total non-current assets | 8,482 | 5,986 |
Current assets | ||
Prepayments, accrued income and other receivables | 5,133 | 4,628 |
Current income tax receivable | 5,143 | 9,822 |
Cash and cash equivalents | 71,027 | 87,356 |
Total current assets | 81,303 | 101,806 |
Total assets | 89,785 | 107,792 |
Capital and reserves | ||
Share capital and share premium | 143,136 | 142,937 |
Other reserves | 70,395 | 66,887 |
Accumulated deficit | (136,084) | (110,594) |
Total equity attributable to equity holders of the Company | 77,447 | 99,230 |
Non-current liabilities | ||
Provisions | 46 | 46 |
Lease liabilities | 195 | 367 |
Total non-current liabilities | 241 | 413 |
Current liabilities | ||
Trade payables | 3,891 | 2,257 |
Payroll taxes and social security | 152 | 177 |
Accrued expenditure | 7,811 | 5,437 |
Lease liabilities | 243 | 278 |
Total current liabilities | 12,097 | 8,149 |
Total liabilities | 12,338 | 8,562 |
Total equity and liabilities | £ 89,785 | £ 107,792 |
Unaudited Condensed Consolida_4
Unaudited Condensed Consolidated Statements of Changes In Equity - GBP (£) £ in Thousands | Total | Share Capital [member] | Share Premium [member] | Own Share Reserve [member] | Share Option Reserve [member] | Foreign Currency Translation Reserve [member] | Capital Reserve [member] | Accumulated Deficit [member] |
Beginning balance at Dec. 31, 2019 | £ 63,522 | £ 1,299 | £ 79,541 | £ (339) | £ 20,620 | £ (10) | £ 42,466 | £ (80,055) |
Loss for the period | (18,421) | (18,421) | ||||||
Other comprehensive income (loss) for the year | 7 | 7 | ||||||
Total comprehensive loss for the period | (18,414) | 7 | (18,421) | |||||
Share-based payments | 3,069 | 3,069 | ||||||
Exercise of share options | 15 | 1 | 14 | (68) | 68 | |||
Lapse of share options | (5) | 5 | ||||||
Issue of share capital | 66,581 | 747 | 65,834 | |||||
Share issue expenses | (4,499) | (4,499) | ||||||
Ending balance at Sep. 30, 2020 | 110,274 | 2,047 | 140,890 | (339) | 23,616 | (3) | 42,466 | (98,403) |
Beginning balance at Dec. 31, 2020 | 99,230 | 2,047 | 140,890 | (339) | 24,782 | (22) | 42,466 | (110,594) |
Loss for the period | (26,889) | (26,889) | ||||||
Other comprehensive income (loss) for the year | 6 | 6 | ||||||
Total comprehensive loss for the period | (26,883) | 6 | (26,889) | |||||
Share-based payments | 4,919 | 4,919 | ||||||
Exercise of share options | 181 | 40 | 159 | (1,221) | 1,203 | |||
Lapse of share options | (196) | 196 | ||||||
Ending balance at Sep. 30, 2021 | £ 77,447 | £ 2,087 | £ 141,049 | £ (339) | £ 28,284 | £ (16) | £ 42,466 | £ (136,084) |
Unaudited Condensed Consolida_5
Unaudited Condensed Consolidated Statements of Cash Flows - GBP (£) £ in Thousands | 9 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Cash flows from operating activities | ||
Loss for the period | £ (26,889) | £ (18,421) |
Adjustments for: | ||
Income tax credit | (5,198) | (3,797) |
Amortization and depreciation | 673 | 667 |
Finance income | (81) | (234) |
Interest expense on lease liabilities | 15 | 20 |
Share-based payments | 4,919 | 3,069 |
Net foreign exchange gains | (533) | (619) |
Cash flows from (used in) operations before changes in working capital | (27,094) | (19,315) |
Movements in working capital: | ||
Increase in prepayments, accrued income and other receivables | (497) | (408) |
Increase in trade payables | 1,634 | 1,778 |
Increase in payroll taxes, social security and accrued expenditure | 2,333 | 1,153 |
Movements in working capital | 3,470 | 2,523 |
Cash used in operations | (23,624) | (16,792) |
Net income tax received | 9,888 | 4,152 |
Net cash used in operating activities | (13,736) | (12,640) |
Cash flows from investing activities | ||
Interest received | 79 | 300 |
Payments for property, plant and equipment | (43) | (350) |
Payments for intangible assets | (537) | (1,079) |
Payments for other non-current assets | (2,597) | |
Net cash used in investing activities | (3,098) | (1,129) |
Cash flows from financing activities | ||
Payments of lease liabilities | (222) | (223) |
Proceeds from issue of share capital – exercise of share options | 198 | 15 |
Proceeds from issue of share capital | 0 | 66,581 |
Share issue expenses | (4,499) | |
Net cash (used in) from financing activities | (24) | 61,874 |
Net (decrease) increase in cash and cash equivalents | (16,858) | 48,105 |
Cash and cash equivalents at beginning of period | 87,356 | 51,962 |
Effect of exchange rate changes on cash and cash equivalents | 529 | 611 |
Cash and cash equivalents at end of period | £ 71,027 | £ 100,678 |
General Information
General Information | 9 Months Ended |
Sep. 30, 2021 | |
Disclosure Of General Information About Financial Statements [Abstract] | |
General information | 1. General information NuCana plc (“NuCana” or the “Company”) is a clinical-stage biopharmaceutical company developing a portfolio of new medicines to treat cancer. NuCana is harnessing the power of phosphoramidate chemistry to generate new medicines called ProTides. These compounds have the potential to improve cancer treatment by enhancing the efficacy and safety of several current standards of care. The Company has ordinary shares in the form of American Depositary Shares (“ADSs”) registered with the US Securities and Exchange Commission (the “SEC”) and has been listed on The Nasdaq Global Select Market (“Nasdaq”) since October 2, 2017. The Company is incorporated in England and Wales and domiciled in the United Kingdom. The Company’s registered office is located at 77/78 Cannon Street, London EC4N 6AF, United Kingdom and its principal place of business is located at 3 Lochside Way, Edinburgh, EH12 9DT, United Kingdom. The Company has three wholly owned subsidiaries, NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited (together referred to as the “Group”). The financial information presented in these unaudited condensed consolidated financial statements does not constitute the Group’s statutory accounts within the meaning of section 434 of the U.K. Companies Act 2006. The Group’s statutory accounts for the year ended December 31, 2020 have been reported on by the Company’s auditor and delivered to the Registrar of Companies. The report of the auditor was (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498 (2) or (3) of the Companies Act 2006. |
Significant Accounting Policies
Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2021 | |
Disclosure Of Summary Of Significant Accounting Policies [Abstract] | |
Significant accounting policies | 2. Significant accounting policies Basis of preparation The unaudited condensed consolidated financial statements (the “financial statements”) for the three months and nine months ended September 30, 2021 have been prepared in accordance with International Accounting Standard 34, “ Interim Financial Reporting ” The financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Company’s annual financial statements for the year ended December 31, 2020. In the opinion of management, these unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair statement of the results of operations, financial position and cash flows. The results of operations for the three months and nine months ended September 30, 2021 are not necessarily indicative of the results that can be expected for the Company’s fiscal year ending December 31, 2021. Going concern In common with many companies in the biopharmaceutical sector, the Company incurs significant expenditure in its early years as it researches and develops its potential products for market. The Company’s board of directors, having reviewed the operating budgets and development plans, considers that the Company has adequate resources to continue in operation for the foreseeable future. The board of directors is therefore satisfied that it is appropriate to adopt the going concern basis of accounting in preparing the financial statements. The Company believes that its cash and cash equivalents of £71.0 million at September 30, 2021 will be sufficient to fund its current operating plan for at least the next 12 months. Further, the directors have conducted an assessment of the impact of COVID-19 As the Company continues to incur losses, the transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and achieving a level of revenues adequate to support its cost structure. The Company may never achieve profitability, and unless and until it does, it will continue to need to raise additional capital. There can be no assurances, however, that additional funding will be available on acceptable terms. COVID-19 In response to the spread of COVID-19, on-site During the early months of the pandemic the Company announced that there was some temporary interruption to the enrollment of new patients in the Company’s ongoing clinical trials. In May 2020, the Company further announced that enrollment of new patients in the Company’s clinical trials had re-commenced. COVID-19 COVID-19. COVID-19 Judgements and estimates The accounting estimates and judgements made by management in applying the Group’s accounting policies that have the most significant effect on the amounts included within these financial statements, were the same as those that applied to the annual financial statements for the year ended December 31, 2020. |
Income Tax
Income Tax | 9 Months Ended |
Sep. 30, 2021 | |
Major Components Of Tax Expense Income [Abstract] | |
Income tax | 3. Income tax For the Three Months Ended September 30, For the Nine Months Ended 2021 2020 2021 2020 (in thousands) (in thousands) £ £ £ £ Current tax: In respect of current period U.K. 1,845 1,230 5,139 3,834 In respect of current period U.S. — — — (1 ) In respect of prior period U.K. 70 (22 ) 70 (22 ) 1,915 1,208 5,209 3,811 Deferred tax: In respect of current period U.S. (4 ) (4 ) (11 ) (13 ) In respect of prior period U.S. — — — (1 ) Income tax credit 1,911 1,204 5,198 3,797 The income tax credit recognized primarily represents the U.K. research and development tax credit. In the United Kingdom, the Company is able to surrender some of its losses for a cash rebate of up to 33.35% of expenditure related to eligible research and development projects. September 30, December 31, (in thousands) £ £ Current income tax receivable U.K. tax 5,140 9,818 U.S. tax 3 4 5,143 9,822 Deferred tax asset U.S. deferred tax asset 34 44 |
Basic and Diluted Loss Per Shar
Basic and Diluted Loss Per Share | 9 Months Ended |
Sep. 30, 2021 | |
Earnings Per Share [Abstract] | |
Basic and diluted loss per share | 4. Basic and diluted loss per share For the Three Months Ended September 30, For the Nine Months Ended 2021 2020 2021 2020 (in thousands, except per share data) £ £ £ £ Loss for the period (8,041 ) (8,394 ) (26,889 ) (18,421 ) Basic and diluted weighted average number of shares 52,165 35,093 51,994 33,419 £ £ £ £ Basic and diluted loss per share (0.15 ) (0.24 ) (0.52 ) (0.55 ) Basic loss per share is calculated by dividing the loss for the period attributable to the equity holders of the Company by the weighted average number of shares outstanding during the period. The potential shares issued through equity settled transactions were considered to be anti-dilutive as they would have decreased the loss per share and were therefore excluded from the calculation of diluted loss per share. |
Intangible Assets
Intangible Assets | 9 Months Ended |
Sep. 30, 2021 | |
Disclosure Of Intangible Assets [Abstract] | |
Intangible assets | 5. Intangible assets Intangible assets comprise patents with a carrying value of £4.8 million as of September 30, 2021 (as of December 31, 2020: £4.6 million) and computer software with a carrying value of £0.1 million as of September 30, 2021 (as of December 31, 2020: £0.2 million). During the nine months ended September 30, 2021, the Company acquired intangible assets with a cost of £0.5 million in relation to patents. There were no disposals of intangible assets in the nine months ended September 30, 2021. |
Other Non-Current Assets
Other Non-Current Assets | 9 Months Ended |
Sep. 30, 2021 | |
Disclosure Of Other Noncurrent Assets [Abstract] | |
Other non-current assets | 6. Other non-current September 30, December 31, (in thousands) £ £ Other non-current 2,600 — In April 2021, the Company initiated legal proceedings against Gilead Sciences Ireland UC and Gilead Sciences GmbH for patent infringement in Germany. In June 2021, the Company was requested by the court to provide the defendants with a security of €3.0 million (£2.6 million) to cover the legal costs of the defendants in the event that the Company is unsuccessful in the final outcome of the legal proceedings. In July 2021, the Company provided the security in accordance with the court order by depositing €3.0 million with the court. The extent to which the sum deposited will be reimbursed to the Company is dependent on a range of potential outcomes, and the timing of those outcomes, with respect to the patent infringement litigation in Germany, which is currently indeterminable. |
Cash and Cash Equivalents
Cash and Cash Equivalents | 9 Months Ended |
Sep. 30, 2021 | |
Cash And Cash Equivalents [Abstract] | |
Cash and cash equivalents | 7. Cash and cash equivalents September 30, December 31, (in thousands) £ £ Cash and cash equivalents 71,027 87,356 Cash and cash equivalents comprise cash at banks with maturity terms of three months or less, and is subject to insignificant risk of changes in value. Cash at banks earns interest at fixed or variable rates based on the terms agreed for each account. |
Share-based Payments
Share-based Payments | 9 Months Ended |
Sep. 30, 2021 | |
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract] | |
Share-based payments | 8. Share-based payments The Company has six share-based payment plans for employees, directors and consultants. The share options granted will be settled in equity. Options granted under each of the six plans have a maximum life of 10 years. If the Company determines, and at its discretion, an arrangement may be made under the 2020 Long-Term Incentive Plan to substitute the right to acquire shares with a cash alternative of equivalent value. As detailed in the table below, during the nine months ended September 30, 2021, 4,164,913 share options were granted under the 2020 Long-Term Incentive Plan (nine months ended September 30, 2020: 2,585,639 share options granted under the 2016 Share Option Scheme and 2020 Long-Term Incentive Plan). Options granted under these plans will vest if the option holder remains under respective contract of employment or contract of service for the agreed vesting period. The share options granted in the period will vest over a period of up to four The fair values of options granted were determined using the Black-Scholes model that takes into account factors specific to the share incentive plan such as the assumption that the options are exercised at a point in time of up to two years after vesting. This has been incorporated into the measurement by means of actuarial modelling. As NuCana plc was unlisted until October 2, 2017, it is not possible to derive historical volatility from the Company’s ADSs prior to October 2017. For options with an estimated life of greater than three years, the underlying expected volatility was determined by using the average of the historical volatility of similar listed entities as a proxy. Options granted with an estimated life of three years or less, have been valued using the Company’s own historical volatility rates. Options granted on January 13, 2021 February 10, 2021 February 10, 2021 February 10, 2021 Vesting dates January 13, 2022 February 10, 2022 February 10, 2022 February 10, 2022 January 13, 2023 February 10, 2023 February 10, 2023 February 10, 2023 January 13, 2024 February 10, 2024 February 10, 2024 February 10, 2024 January 13, 2025 February 10, 2025 February 10, 2025 February 10, 2025 Volatility 81.42 % 81.45 % 87.66 % 83.86 % Dividend yield 0 % 0 % 0 % 0 % Risk-free investment rate 0.01 % 0.11 % 0.01 % 0.05 % Fair value of option at grant date £ 2.37 £ 2.74 £ 4.49 £ 4.49 Fair value of share at grant date £ 3.92 £ 4.53 £ 4.53 £ 4.53 Exercise price at date of grant £ 3.92 £ 4.53 £ 0.04 £ 0.04 Lapse date January 13, 2031 February 10, 2031 — February 10, 2031 Expected option life (years) 4.5 4.5 2.5 3.5 Number of options granted 200,000 872,775 91,888 337,000 August 11, 2021 September 15, 2021 September 15, 2021 September 15, 2021 Vesting dates August 11, 2022 Sept. 15, 2022 Sept. 15, 2022 Sept. 15, 2022 August 11, 2023 Sept. 15, 2023 Sept. 15, 2023 Sept. 15, 2023 August 11, 2024 Sept. 15, 2024 Sept. 15, 2024 Sept. 15, 2024 August 11, 2025 Sept. 15, 2025 Sept. 15, 2025 Sept. 15, 2025 Volatility 81.07 % 79.60 % 82.06 % 80.90 % Dividend yield 0 % 0 % 0 % 0 % Risk-free investment rate 0.28 % 0.21 % 0.29 % 0.36 % Fair value of option at grant date £ 0.95 £ 1.67 £ 1.67 £ 1.04 Fair value of share at grant date £ 1.57 £ 1.71 £ 1.71 £ 1.71 Exercise price at date of grant £ 1.57 £ 0.04 £ 0.04 £ 1.71 Lapse date August 11, 2031 — Sept. 15, 2031 Sept. 15, 2031 Expected option life (years) 4.5 2.5 3.5 4.5 Number of options granted 430,000 140,650 603,900 1,488,700 For the three months ended September 30, 2021, the Company has recognized £1.3 million of share-based payment expense in the statement of operations (three months ended September 30, 2020: £1.4 million). For the nine months ended September 30, 2021, the Company has recognized £4.9 million of share-based payment expense in the statement of operations (nine months ended September 30, 2020: £3.1 million). |
Share Capital and Share Premium
Share Capital and Share Premium | 9 Months Ended |
Sep. 30, 2021 | |
Disclosure Of Classes Of Share Capital [Abstract] | |
Share capital and share premium | 9. Share capital and share premium September 30, December 31, (in thousands) £ £ Share capital 2,087 2,047 Share premium 141,049 140,890 143,136 142,937 September 30, December 31, Number (in thousands) Issued share capital comprises: Ordinary shares of £0.04 each 52,180 51,175 Number of Share Share (in thousands) £ £ Fully paid shares: Balance at December 31, 2020 51,175 2,047 140,890 Issue of shares on exercise of options 1,005 40 159 Balance at September 30, 2021 52,180 2,087 141,049 |
Contingent Liabilities
Contingent Liabilities | 9 Months Ended |
Sep. 30, 2021 | |
Disclosure Of Contingent Liabilities [Abstract] | |
Contingent liabilities | 10. Contingent liabilities Under its U.K. share-based payment plan, the Company granted unapproved share options that have fully vested. If and when these share options are exercised, the Company will be liable for the Employer Class 1 National Insurance payable to HMRC in the United Kingdom. This contingent liability will be determined based on the market value of the shares on exercise less the exercise price paid by the option holders, at the prevailing rate of Employer National Insurance (currently 13.8%). Based on the closing price of the Company’s ADSs on The Nasdaq Global Select Market on September 30, 2021, the last trading day of the period to which these financial statements relate, and assuming full exercise of all outstanding and vested unapproved share options on that date, the Employer National Insurance contingent liability would have been £0.5 million (December 31, 2020: £0.8 million). As referenced in Note 6, in July 2021 the Company provided a security of €3.0 million to cover the legal costs of Gilead Sciences Ireland UC and Gilead Sciences GmbH in the event that the Company is unsuccessful in the final outcome of the patent infringement litigation in Germany. Any cost reimbursement by the Company to the defendants is dependent on a range of potential outcomes, and the timing of those outcomes, with respect to the litigation, which are currently indeterminable. Therefore, no provision has been recognised with respect to these legal costs. |
Significant Accounting Polici_2
Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2021 | |
Disclosure Of Summary Of Significant Accounting Policies [Abstract] | |
Basis of preparation | Basis of preparation The unaudited condensed consolidated financial statements (the “financial statements”) for the three months and nine months ended September 30, 2021 have been prepared in accordance with International Accounting Standard 34, “ Interim Financial Reporting ” The financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Company’s annual financial statements for the year ended December 31, 2020. In the opinion of management, these unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair statement of the results of operations, financial position and cash flows. The results of operations for the three months and nine months ended September 30, 2021 are not necessarily indicative of the results that can be expected for the Company’s fiscal year ending December 31, 2021. |
Going concern | Going concern In common with many companies in the biopharmaceutical sector, the Company incurs significant expenditure in its early years as it researches and develops its potential products for market. The Company’s board of directors, having reviewed the operating budgets and development plans, considers that the Company has adequate resources to continue in operation for the foreseeable future. The board of directors is therefore satisfied that it is appropriate to adopt the going concern basis of accounting in preparing the financial statements. The Company believes that its cash and cash equivalents of £71.0 million at September 30, 2021 will be sufficient to fund its current operating plan for at least the next 12 months. Further, the directors have conducted an assessment of the impact of COVID-19 As the Company continues to incur losses, the transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and achieving a level of revenues adequate to support its cost structure. The Company may never achieve profitability, and unless and until it does, it will continue to need to raise additional capital. There can be no assurances, however, that additional funding will be available on acceptable terms. |
COVID-19 | COVID-19 In response to the spread of COVID-19, on-site During the early months of the pandemic the Company announced that there was some temporary interruption to the enrollment of new patients in the Company’s ongoing clinical trials. In May 2020, the Company further announced that enrollment of new patients in the Company’s clinical trials had re-commenced. COVID-19 COVID-19. COVID-19 |
Judgements and estimates | Judgements and estimates The accounting estimates and judgements made by management in applying the Group’s accounting policies that have the most significant effect on the amounts included within these financial statements, were the same as those that applied to the annual financial statements for the year ended December 31, 2020. |
Income Tax (Tables)
Income Tax (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Major Components Of Tax Expense Income [Abstract] | |
Schedule of Major Components of Income Tax | For the Three Months Ended September 30, For the Nine Months Ended 2021 2020 2021 2020 (in thousands) (in thousands) £ £ £ £ Current tax: In respect of current period U.K. 1,845 1,230 5,139 3,834 In respect of current period U.S. — — — (1 ) In respect of prior period U.K. 70 (22 ) 70 (22 ) 1,915 1,208 5,209 3,811 Deferred tax: In respect of current period U.S. (4 ) (4 ) (11 ) (13 ) In respect of prior period U.S. — — — (1 ) Income tax credit 1,911 1,204 5,198 3,797 September 30, December 31, (in thousands) £ £ Current income tax receivable U.K. tax 5,140 9,818 U.S. tax 3 4 5,143 9,822 Deferred tax asset U.S. deferred tax asset 34 44 |
Basic and Diluted Loss Per Sh_2
Basic and Diluted Loss Per Share (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Earnings Per Share [Abstract] | |
Schedule of Basic and Diluted Loss Per Share | For the Three Months Ended September 30, For the Nine Months Ended 2021 2020 2021 2020 (in thousands, except per share data) £ £ £ £ Loss for the period (8,041 ) (8,394 ) (26,889 ) (18,421 ) Basic and diluted weighted average number of shares 52,165 35,093 51,994 33,419 £ £ £ £ Basic and diluted loss per share (0.15 ) (0.24 ) (0.52 ) (0.55 ) |
Other Non-Current Assets (Table
Other Non-Current Assets (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Disclosure Of Other Noncurrent Assets [Abstract] | |
Disclosure of Other Non-current Assets | September 30, December 31, (in thousands) £ £ Other non-current 2,600 — |
Cash and Cash Equivalents (Tabl
Cash and Cash Equivalents (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Cash And Cash Equivalents [Abstract] | |
Schedule of Cash and Cash Equivalents | September 30, December 31, (in thousands) £ £ Cash and cash equivalents 71,027 87,356 |
Share-based Payments (Tables)
Share-based Payments (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Text block [abstract] | |
Summary of Principal Assumptions Used for Valuation of Share Options | Options granted on January 13, 2021 February 10, 2021 February 10, 2021 February 10, 2021 Vesting dates January 13, 2022 February 10, 2022 February 10, 2022 February 10, 2022 January 13, 2023 February 10, 2023 February 10, 2023 February 10, 2023 January 13, 2024 February 10, 2024 February 10, 2024 February 10, 2024 January 13, 2025 February 10, 2025 February 10, 2025 February 10, 2025 Volatility 81.42 % 81.45 % 87.66 % 83.86 % Dividend yield 0 % 0 % 0 % 0 % Risk-free investment rate 0.01 % 0.11 % 0.01 % 0.05 % Fair value of option at grant date £ 2.37 £ 2.74 £ 4.49 £ 4.49 Fair value of share at grant date £ 3.92 £ 4.53 £ 4.53 £ 4.53 Exercise price at date of grant £ 3.92 £ 4.53 £ 0.04 £ 0.04 Lapse date January 13, 2031 February 10, 2031 — February 10, 2031 Expected option life (years) 4.5 4.5 2.5 3.5 Number of options granted 200,000 872,775 91,888 337,000 August 11, 2021 September 15, 2021 September 15, 2021 September 15, 2021 Vesting dates August 11, 2022 Sept. 15, 2022 Sept. 15, 2022 Sept. 15, 2022 August 11, 2023 Sept. 15, 2023 Sept. 15, 2023 Sept. 15, 2023 August 11, 2024 Sept. 15, 2024 Sept. 15, 2024 Sept. 15, 2024 August 11, 2025 Sept. 15, 2025 Sept. 15, 2025 Sept. 15, 2025 Volatility 81.07 % 79.60 % 82.06 % 80.90 % Dividend yield 0 % 0 % 0 % 0 % Risk-free investment rate 0.28 % 0.21 % 0.29 % 0.36 % Fair value of option at grant date £ 0.95 £ 1.67 £ 1.67 £ 1.04 Fair value of share at grant date £ 1.57 £ 1.71 £ 1.71 £ 1.71 Exercise price at date of grant £ 1.57 £ 0.04 £ 0.04 £ 1.71 Lapse date August 11, 2031 — Sept. 15, 2031 Sept. 15, 2031 Expected option life (years) 4.5 2.5 3.5 4.5 Number of options granted 430,000 140,650 603,900 1,488,700 |
Share Capital and Share Premi_2
Share Capital and Share Premium (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Disclosure Of Classes Of Share Capital [Abstract] | |
Summary of Share Capital and Share Premium | September 30, December 31, (in thousands) £ £ Share capital 2,087 2,047 Share premium 141,049 140,890 143,136 142,937 September 30, December 31, Number (in thousands) Issued share capital comprises: Ordinary shares of £0.04 each 52,180 51,175 |
Summary of Movement in the Share Capital | Number of Share Share (in thousands) £ £ Fully paid shares: Balance at December 31, 2020 51,175 2,047 140,890 Issue of shares on exercise of options 1,005 40 159 Balance at September 30, 2021 52,180 2,087 141,049 |
General Information - Additiona
General Information - Additional Information (Detail) | 9 Months Ended |
Sep. 30, 2021Subsidiary | |
Disclosure Of General Information About Financial Statements [Abstract] | |
Description of nature of entity's operations | clinical-stage biopharmaceutical company developing a portfolio of new medicines to treat cancer |
Name of reporting entity | NuCana plc |
Domicile of entity | United Kingdom |
Country of incorporation | England and Wales |
Number of subsidiaries | 3 |
Name of subsidiary | NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited |
Significant Accounting Polici_3
Significant Accounting Policies - Additional Information (Detail) - GBP (£) £ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | Dec. 31, 2019 |
Disclosure Of Summary Of Significant Accounting Policies [Abstract] | ||||
Cash and cash equivalents | £ 71,027 | £ 87,356 | £ 100,678 | £ 51,962 |
Income Tax - Schedule of Major
Income Tax - Schedule of Major Components of Income Tax Credit (Detail) - GBP (£) £ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Current tax: | ||||
Total current tax | £ 1,915 | £ 1,208 | £ 5,209 | £ 3,811 |
Deferred tax: | ||||
Income tax credit | 1,911 | 1,204 | 5,198 | 3,797 |
U.K. [member] | ||||
Current tax: | ||||
In respect of current period | 1,845 | 1,230 | 5,139 | 3,834 |
In respect of prior period | 70 | (22) | 70 | (22) |
U.S. [member] | ||||
Current tax: | ||||
In respect of current period | 0 | (1) | ||
Deferred tax: | ||||
In respect of current period | £ (4) | £ (4) | £ (11) | (13) |
In respect of prior period | £ (1) |
Income Tax - Additional Informa
Income Tax - Additional Information (Detail) | 9 Months Ended |
Sep. 30, 2021 | |
U.K. [member] | |
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |
Percentage of losses surrendered for R&D tax credit | 33.35% |
Income Tax - Schedule of Majo_2
Income Tax - Schedule of Major Components of Income Tax Assets (Detail) - GBP (£) £ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Current income tax receivable | ||
Current income tax receivable | £ 5,143 | £ 9,822 |
Deferred tax asset | ||
Deferred tax asset | 34 | 44 |
U.K. [member] | ||
Current income tax receivable | ||
Current income tax receivable | 5,140 | 9,818 |
U.S. [member] | ||
Current income tax receivable | ||
Current income tax receivable | 3 | 4 |
Deferred tax asset | ||
Deferred tax asset | £ 34 | £ 44 |
Basic and Diluted Loss per Sh_3
Basic and Diluted Loss per Share - Schedule of Basic and Diluted Loss Per Share (Detail) - GBP (£) £ / shares in Units, £ in Thousands, shares in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Earnings Per Share [Abstract] | ||||
Loss for the period | £ (8,041) | £ (8,394) | £ (26,889) | £ (18,421) |
Basic and diluted weighted average number of shares | 52,165 | 35,093 | 51,994 | 33,419 |
Basic and diluted loss per share | £ (0.15) | £ (0.24) | £ (0.52) | £ (0.55) |
Intangible Assets - Additional
Intangible Assets - Additional Information (Detail) - GBP (£) £ in Thousands | 9 Months Ended | |
Sep. 30, 2021 | Dec. 31, 2020 | |
Disclosure of detailed information about intangible assets [line items] | ||
Intangible assets, carrying value | £ 4,896 | £ 4,753 |
Patents [member] | ||
Disclosure of detailed information about intangible assets [line items] | ||
Intangible assets, carrying value | 4,800 | 4,600 |
Intangible assets, acquired | 500 | |
Computer Software [member] | ||
Disclosure of detailed information about intangible assets [line items] | ||
Intangible assets, carrying value | £ 100 | £ 200 |
Other Non-Current Asstes - Add
Other Non-Current Asstes - Additional Information (Detail) £ in Millions | Jul. 01, 2021GBP (£) | Jul. 01, 2021EUR (€) | Jun. 30, 2021GBP (£) | Jun. 30, 2021EUR (€) |
Disclosure Of Other Noncurrent Assets [Abstract] | ||||
Security deposit to cover legal costs | £ 2.6 | € 3,000,000 | ||
Payment of security deposit to cover legal costs | £ 3 | € 3,000 |
Other Non-Current Assets - Disc
Other Non-Current Assets - Disclosure of Other Non-current Assets (Details) - GBP (£) £ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Disclosure Of Other Noncurrent Assets [Line Items] | ||
Other non-current assets | £ 2,600 | £ 0 |
Cash and Cash Equivalents - Sch
Cash and Cash Equivalents - Schedule of Detailed Information About Cash and Cash Equivalents (Detail) - GBP (£) £ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | Dec. 31, 2019 |
Cash And Cash Equivalents [Abstract] | ||||
Cash and cash equivalents | £ 71,027 | £ 87,356 | £ 100,678 | £ 51,962 |
Share-based Payments - Addition
Share-based Payments - Additional Information (Details) £ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021GBP (£) | Sep. 30, 2020GBP (£) | Sep. 30, 2021GBP (£)shares | Sep. 30, 2020GBP (£)shares | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Share-based payment expense | £ | £ 1.3 | £ 1.4 | £ 4.9 | £ 3.1 |
Long-Term Incentive Plan [member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Number of share options granted in share-based payment arrangement | shares | 4,164,913 | 2,585,639 | ||
Share options granted, vesting period | 4 years |
Share Based Payments - Summary
Share Based Payments - Summary of Principal Assumptions used for Valuation of Share Options (Detail) - 9 months ended Sep. 30, 2021 - 2020 Share Options [member] | GBP (£)sharesSubsidiaryyr£ / shares | GBP (£)sharesSubsidiaryyr$ / shares |
Grant Date June 10, 2020 [Member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Lapse date | Jan. 13, 2031 | Jan. 13, 2031 |
Grant Date January 13, 2021 [Member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Volatility | 81.42% | 81.42% |
Dividend yield | 0.00% | 0.00% |
Risk-free investment rate | 0.01% | 0.01% |
Fair value of option at grant date | £ | £ 2,370 | £ 2,370 |
Fair value of share at grant date | £ 3.92 | |
Exercise price at date of grant | £ 3.92 | |
Expected option life (years) | yr | 4.5 | 4.5 |
Number of options granted | shares | 200,000 | 200,000 |
Grant Date January 13, 2021 [Member] | Vesting Dates One [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Jan. 13, 2022 | Jan. 13, 2022 |
Grant Date January 13, 2021 [Member] | Vesting Dates Two [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Jan. 13, 2023 | Jan. 13, 2023 |
Grant Date January 13, 2021 [Member] | Vesting Dates Three [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Jan. 13, 2024 | Jan. 13, 2024 |
Grant Date January 13, 2021 [Member] | Vesting Dates Four [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Jan. 13, 2025 | Jan. 13, 2025 |
Grant Date February 10, 2021 [Member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Volatility | 81.45% | 81.45% |
Dividend yield | 0.00% | 0.00% |
Risk-free investment rate | 0.11% | 0.11% |
Fair value of option at grant date | £ | £ 2,740 | £ 2,740 |
Fair value of share at grant date | £ 4.53 | |
Exercise price at date of grant | £ 4.53 | |
Lapse date | Feb. 10, 2031 | Feb. 10, 2031 |
Expected option life (years) | yr | 4.5 | 4.5 |
Number of options granted | shares | 872,775 | 872,775 |
Grant Date February 10, 2021 [Member] | Vesting Dates One [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Feb. 10, 2022 | Feb. 10, 2022 |
Grant Date February 10, 2021 [Member] | Vesting Dates Two [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Feb. 10, 2023 | Feb. 10, 2023 |
Grant Date February 10, 2021 [Member] | Vesting Dates Three [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Feb. 10, 2024 | Feb. 10, 2024 |
Grant Date February 10, 2021 [Member] | Vesting Dates Four [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Feb. 10, 2025 | Feb. 10, 2025 |
Grant Date February 10, 2021 One [Member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Volatility | 87.66% | 87.66% |
Dividend yield | 0.00% | 0.00% |
Risk-free investment rate | 0.01% | 0.01% |
Fair value of option at grant date | £ | £ 4,490 | £ 4,490 |
Fair value of share at grant date | £ 4.53 | |
Exercise price at date of grant | £ 0.04 | |
Expected option life (years) | yr | 2.5 | 2.5 |
Number of options granted | shares | 91,888 | 91,888 |
Grant Date February 10, 2021 One [Member] | Vesting Dates One [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Feb. 10, 2022 | Feb. 10, 2022 |
Grant Date February 10, 2021 One [Member] | Vesting Dates Two [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Feb. 10, 2023 | Feb. 10, 2023 |
Grant Date February 10, 2021 One [Member] | Vesting Dates Three [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Feb. 10, 2024 | Feb. 10, 2024 |
Grant Date February 10, 2021 One [Member] | Vesting Dates Four [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Feb. 10, 2025 | Feb. 10, 2025 |
Grant Date February 10, 2021 Two [Member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Volatility | 83.86% | 83.86% |
Dividend yield | 0.00% | 0.00% |
Risk-free investment rate | 0.05% | 0.05% |
Fair value of option at grant date | £ | £ 4,490 | £ 4,490 |
Fair value of share at grant date | $ / shares | £ 4.53 | |
Exercise price at date of grant | $ / shares | £ 0.04 | |
Lapse date | Feb. 10, 2031 | Feb. 10, 2031 |
Expected option life (years) | yr | 3.5 | 3.5 |
Number of options granted | Subsidiary | 337,000 | 337,000 |
Grant Date February 10, 2021 Two [Member] | Vesting Dates One [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Feb. 10, 2022 | Feb. 10, 2022 |
Grant Date February 10, 2021 Two [Member] | Vesting Dates Two [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Feb. 10, 2023 | Feb. 10, 2023 |
Grant Date February 10, 2021 Two [Member] | Vesting Dates Three [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Feb. 10, 2024 | Feb. 10, 2024 |
Grant Date February 10, 2021 Two [Member] | Vesting Dates Four [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Feb. 10, 2025 | Feb. 10, 2025 |
Grant Date August 11, 2021 [Member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Volatility | 81.07% | 81.07% |
Dividend yield | 0.00% | 0.00% |
Risk-free investment rate | 0.28% | 0.28% |
Fair value of option at grant date | £ | £ 950 | £ 950 |
Fair value of share at grant date | £ 1.57 | |
Exercise price at date of grant | £ 1.57 | |
Lapse date | Aug. 11, 2031 | Aug. 11, 2031 |
Expected option life (years) | yr | 4.5 | 4.5 |
Number of options granted | Subsidiary | 430,000 | 430,000 |
Grant Date August 11, 2021 [Member] | Vesting Dates One [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Aug. 11, 2022 | Aug. 11, 2022 |
Grant Date August 11, 2021 [Member] | Vesting Dates Two [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Aug. 11, 2023 | Aug. 11, 2023 |
Grant Date August 11, 2021 [Member] | Vesting Dates Three [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Aug. 11, 2024 | Aug. 11, 2024 |
Grant Date August 11, 2021 [Member] | Vesting Dates Four [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Aug. 11, 2025 | Aug. 11, 2025 |
Grant Date September 15, 2021 [Member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Volatility | 79.60% | 79.60% |
Dividend yield | 0.00% | 0.00% |
Risk-free investment rate | 0.21% | 0.21% |
Fair value of option at grant date | £ | £ 1,670 | £ 1,670 |
Fair value of share at grant date | £ 1.71 | |
Exercise price at date of grant | £ 0.04 | |
Expected option life (years) | yr | 2.5 | 2.5 |
Number of options granted | Subsidiary | 140,650 | 140,650 |
Grant Date September 15, 2021 [Member] | Vesting Dates One [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Sep. 15, 2022 | Sep. 15, 2022 |
Grant Date September 15, 2021 [Member] | Vesting Dates Two [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Sep. 15, 2023 | Sep. 15, 2023 |
Grant Date September 15, 2021 [Member] | Vesting Dates Three [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Sep. 15, 2024 | Sep. 15, 2024 |
Grant Date September 15, 2021 [Member] | Vesting Dates Four [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Sep. 15, 2025 | Sep. 15, 2025 |
Grant Date September 15 2021 One [Member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Volatility | 82.06% | 82.06% |
Dividend yield | 0.00% | 0.00% |
Risk-free investment rate | 0.29% | 0.29% |
Fair value of option at grant date | £ | £ 1,670 | £ 1,670 |
Fair value of share at grant date | £ 1.71 | |
Exercise price at date of grant | £ 0.04 | |
Lapse date | Sep. 15, 2031 | Sep. 15, 2031 |
Expected option life (years) | yr | 3.5 | 3.5 |
Number of options granted | Subsidiary | 603,900 | 603,900 |
Grant Date September 15 2021 One [Member] | Vesting Dates One [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Sep. 15, 2022 | Sep. 15, 2022 |
Grant Date September 15 2021 One [Member] | Vesting Dates Two [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Sep. 15, 2023 | Sep. 15, 2023 |
Grant Date September 15 2021 One [Member] | Vesting Dates Three [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Sep. 15, 2024 | Sep. 15, 2024 |
Grant Date September 15 2021 One [Member] | Vesting Dates Four [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Sep. 15, 2025 | Sep. 15, 2025 |
Grant Date September 15 2021 Two [Member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Volatility | 80.90% | 80.90% |
Dividend yield | 0.00% | 0.00% |
Risk-free investment rate | 0.36% | 0.36% |
Fair value of option at grant date | £ | £ 1,040 | £ 1,040 |
Fair value of share at grant date | $ / shares | £ 1.71 | |
Exercise price at date of grant | $ / shares | £ 1.71 | |
Lapse date | Sep. 15, 2031 | Sep. 15, 2031 |
Expected option life (years) | yr | 4.5 | 4.5 |
Number of options granted | Subsidiary | 1,488,700 | 1,488,700 |
Grant Date September 15 2021 Two [Member] | Vesting Dates One [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Sep. 15, 2022 | Sep. 15, 2022 |
Grant Date September 15 2021 Two [Member] | Vesting Dates Two [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Sep. 15, 2023 | Sep. 15, 2023 |
Grant Date September 15 2021 Two [Member] | Vesting Dates Three [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Sep. 15, 2024 | Sep. 15, 2024 |
Grant Date September 15 2021 Two [Member] | Vesting Dates Four [member] | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Vesting dates | Sep. 15, 2025 | Sep. 15, 2025 |
Share Capital and Share Premi_3
Share Capital and Share Premium - Summary of Share Capital and Share Premium (Detail) - GBP (£) £ in Thousands, shares in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Disclosure Of Classes Of Share Capital [Abstract] | ||
Share capital | £ 2,087 | £ 2,047 |
Share premium | 141,049 | 140,890 |
Share capital and share premium | £ 143,136 | £ 142,937 |
Ordinary shares of £0.04 each | 52,180 | 51,175 |
Share Capital and Share Premi_4
Share Capital and Share Premium - Summary of Share Capital and Share Premium (Parenthetical) (Detail) | Sep. 30, 2021£ / shares | Dec. 31, 2020$ / shares |
Ordinary shares [member] | ||
Disclosure of classes of share capital [line items] | ||
Par value per share | (per share) | £ 0.04 | $ 0.04 |
Share Capital and Share Premi_5
Share Capital and Share Premium - Summary of Movement in the Share Capital (Detail) £ in Thousands, shares in Thousands | 9 Months Ended | |
Sep. 30, 2021GBP (£)shares | Sep. 30, 2020GBP (£) | |
Disclosure of classes of share capital [line items] | ||
Beginning balance, Shares | shares | 51,175 | |
Beginning balance | £ 99,230 | £ 63,522 |
Issue of shares on exercise of options | shares | 1,005 | |
Issue of shares on exercise of options | £ 181 | 15 |
Ending balance, Shares | shares | 52,180 | |
Ending balance | £ 77,447 | 110,274 |
Share Capital [member] | ||
Disclosure of classes of share capital [line items] | ||
Beginning balance | 2,047 | 1,299 |
Issue of shares on exercise of options | 40 | 1 |
Ending balance | 2,087 | 2,047 |
Share Premium [member] | ||
Disclosure of classes of share capital [line items] | ||
Beginning balance | 140,890 | 79,541 |
Issue of shares on exercise of options | 159 | 14 |
Ending balance | £ 141,049 | £ 140,890 |
Contingent Liabilities - Additi
Contingent Liabilities - Additional Information (Detail) £ in Millions | Jul. 01, 2021GBP (£) | Jul. 01, 2021EUR (€) | Sep. 30, 2021GBP (£) | Dec. 31, 2020GBP (£) |
Disclosure Of Contingent Liabilities [Abstract] | ||||
Prevailing rate of employer national insurance | 13.80% | |||
Employer national insurance contingent liability | £ 0.5 | £ 0.8 | ||
Payment of security deposit to cover legal costs | £ 3 | € 3,000 |